NIH clarifies restrictions on staff after Trump's broad freeze sparked chaos

Clinical trials are proceeding, some purchasing is allowed, and scientists can publish research, an internal memo shows.

January 27, 2025 Check out STAT+

Sponsored By

Adobe STAT+ | NIH clarifies restrictions on staff after Trump's broad freeze sparked chaos Clinical trials are proceeding, some purchasing is allowed, and scientists can publish research, an internal memo shows. By Sarah Owermohle CDC ordered to stop working with WHO immediately, upending expectations of an extended withdrawal Experts said the sudden stoppage was a surprise and would set back work on investigating and trying to stop outbreaks. By Associated Press Bariatric surgery halted progression of liver disease in patients with obesity and cirrhosis, study finds Cirrhosis and other liver diseases are common and hard to treat. But a study shows bariatric surgery can halt its progression. By Elizabeth Cooney CHRISTOPHER BLACK/WHO/AFP via Getty Images Opinion: Who is protecting Americans from Marburg right now? The WHO and the CDC coordinated well when faced with viral outbreaks. This is no time to demolish a well-oiled machine. By Stephanie Psaki STAT+ | Q&A: Why this health AI startup is shutting down "We ran out of money. Plain and simple," Equality AI's CEO Maia Hightower said, days after she decided to shut down her startup. By Brittany Trang STAT+ | Veru says its drug preserved lean mass in patients taking Wegovy The company said its drug enobosarm helped maintain patients' lean mass as they lost fat in a midstage trial, though more data are needed. By Elaine Chen Ethan Swope/AP Opinion: 'Where are our patients?': Three days of searching during the LA fires Gabriel Waterman works with older adults in assisted living facilities and nursing homes. When fire struck LA, he and his team had to find their patients. By Gabriel Waterman STAT+ | Akero drug reverses liver scarring in study of severe MASH patients The performance of Akero's drug, called efruxifermin, in the severe MASH study outperformed investors' expectations. By Adam Feuerstein

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Daily Recap? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser